Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients

Y Morishita, M Watanabe, S Hanawa… - … of Nephrology and …, 2012 - Taylor & Francis
Y Morishita, M Watanabe, S Hanawa, O Iimura, S Tsunematsu, K Ishibashi, E Kusano
International Journal of Nephrology and Renovascular Disease, 2012Taylor & Francis
Objective The long-term effects of aliskiren in hypertensive hemodialysis patients remain to
be elucidated. Design In this post hoc analysis, we followed up 25 hypertensive
hemodialysis patients who completed 8-week aliskiren treatment in a previous study for 20
months to investigate the blood pressure-lowering effect and inhibitory effect on the renin-
angiotensin-aldosterone system. Results Among the 25 patients, eleven patients continued
with aliskiren treatment. Blood pressure (±standard deviation) decreased from …
Objective
The long-term effects of aliskiren in hypertensive hemodialysis patients remain to be elucidated.
Design
In this post hoc analysis, we followed up 25 hypertensive hemodialysis patients who completed 8-week aliskiren treatment in a previous study for 20 months to investigate the blood pressure-lowering effect and inhibitory effect on the renin-angiotensin-aldosterone system.
Results
Among the 25 patients, eleven patients continued with aliskiren treatment. Blood pressure (± standard deviation) decreased from 175 ± 18/80 ± 11 mmHg at baseline to 156 ± 20/76 ± 9 mmHg at month 20. Plasma renin activity, angiotensin I, and angiotensin II decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 (P < 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P < 0.05), angiotensin II (pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P < 0.05)).
Conclusion
Long-term treatment with aliskiren provides effective blood pressure lowering and inhibition of the renin-angiotensin-aldosterone system, which are sustained over 20 months in hypertensive hemodialysis patients.
Taylor & Francis Online